Variantyx Revenue and Competitors

Boston, MA USA

Location

#7513

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Variantyx's estimated annual revenue is currently $52.7M per year.(i)
  • Variantyx's estimated revenue per employee is $236,323
  • Variantyx's total funding is $135M.

Employee Data

  • Variantyx has 223 Employees.(i)
  • Variantyx grew their employee count by 16% last year.

Variantyx's People

NameTitleEmail/Phone
1
Co-Founder and CEOReveal Email/Phone
2
COOReveal Email/Phone
3
VP SalesReveal Email/Phone
4
VP Systems and SecurityReveal Email/Phone
5
VP Customer Support & Laboratory ServicesReveal Email/Phone
6
VP Information SystemsReveal Email/Phone
7
Laboratory DirectorReveal Email/Phone
8
Director, Rare DisordersReveal Email/Phone
9
Medical DirectorReveal Email/Phone
10
Director Authorizations & BenefitsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is Variantyx?

Genomic Unity® testing uses a single method for detection of multiple types of variants to provide one, unified clinical report. PCR-free whole genome sequencing is paired with in-silico analysis to identify small sequence changes, large structural variants, mitochondrial variants and tandem repeat expansions within a single sample. A complete analysis can be ordered directly, or a more targeted analysis can be selected followed by reflexing up to the complete analysis in case no initial results are identified. Learn more at www.variantyx.com/diagnostic-testing/.

keywords:N/A

$135M

Total Funding

223

Number of Employees

$52.7M

Revenue (est)

16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Variantyx News

2021-11-22 - Robert Bosch Venture Capital Invests Approx. $26M in Variantyx

Robert Bosch Venture Capital GmbH, the corporate venture capital company of the Bosch Group, completed an investment in Variantyx Inc., a Framingham, MA-based provider of advanced diagnostics and personalized treatment recommendations for oncology patients’ based on their unique genetic makeup. ...

2021-03-25 - Why Families Need the Closure Whole Genome Sequencing Provides

Haim Neerman, CEO of Variantyx. For medical practitioners expertly trained in the scientific methods of discovery, having a young patient with serious health complications from an undiagnosed condition is about as somber and frustrating as it gets. These feelings are only magnified for parents ...

2021-03-15 - Variantyx Secures $20M in Funding for Whole Genome Sequencing Methodology, Advanced Testing Method that Diagnoses Genetic Disorders

BOSTON--(BUSINESS WIRE)--Mar 15, 2021-- Variantyx, a leader in high complexity hereditary disease testing, today announced that they secured $20M in funding for their Whole Genome Sequencing (WGS)-based testing methodology, an advanced genetic testing method currently used to diagnose rare inhe ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$106M22327%N/A
#2
$34.9M2320%$46M
#3
$97.5M23338%N/A
#4
$15M2388%N/A
#5
$38.6M249-2%N/A